Duality Biotherapeutics, Inc., a biopharmaceutical company based in China, has reached a significant milestone with the dosing of the first patient in its Phase I/IIa clinical study for the in-house developed antibody drug conjugate (ADC) DB-1419. The study is aimed at evaluating the safety and efficacy of DB-1419 in patients with advanced or metastatic solid tumors. This global trial has been granted clinical approvals in both the United States and Australia.
DB-1419 is a promising B7-H3/PD-L1 ADC that has been developed using Duality Bio’s proprietary DIBAC platform. This innovative ADC employs a novel binding and endocytosis mechanism, which has shown to be more effective than conventional monoclonal antibody ADCs. The unique design of DB-1419 is particularly notable for its ability to effectively bypass resistance that can arise from the reduced expression of single targets, positioning it as a potential best-in-class therapy. – Flcube.com
